Investigating the Acute Effects of Blueberry (Poly)Phenols on Vascular Function and Cognition in Healthy Individuals.

Healthy Clinical Trial

— BluLife  

Official title:

Randomised, Double-blind, Placebo Controlled, Crossover Trial Investigating the Acute Effects of Blueberry (Poly)Phenols on Vascular Function and Cognitive Performance in Healthy Individuals Across the Life Course.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03592966
• Other study ID #: BLULIFE
• Status: Completed
• Phase: N/A
• Start date: June 1, 2018
• Est. completion date: May 18, 2021

Study information

• Verified date: May 2021
• Source: King's College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to determine the effect of blueberry (poly)phenol vs placebo on vascular function and cognitive performance with an insight into cerebral blood flow velocity changes, across all ages of the general healthy population.

Description:

Foods rich in certain (poly)phenols, particularly flavonoids, such as berries, have been shown to improve measures of vascular function as well as cognitive performance in human intervention studies. Blueberries are rich in anthocyanins, a subclass of flavonoids that have been widely linked to health benefits, particularly improvements in endothelial function. Research have previously shown that blueberries improve executive functioning and memory in both healthy adults and children. These improvements were seen within 2-5 hours post-consumption of blueberries, a time-course that positively correlates with improvements in vascular function (measured as flow-mediated dilation). This indicates that increases in blood flow may influence improvements in cognitive performance. To date no study has investigated whether blueberry consumption can induce an increase in cerebral blood flow, with subsequent improvements in vascular and cognitive function. In this study, investigators aim to directly link wild blueberry consumption with increased vascular and cerebral blood flow and positive cognitive outcomes in healthy individuals through the life course, between the ages of 8 and 80 years old. Investigators will use a large group of healthy subjects representative of the general public over a wide age range in males and females to evaluate the generalisability of the health benefits of blueberry consumption.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 92
• Est. completion date: May 18, 2021
• Est. primary completion date: October 1, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 8 Years to 80 Years

Eligibility

Inclusion criteria:

• Healthy men and women aged 8-80 years old

• Are able to understand the nature of the study

• Able and willing to give signed written informed consent with the addition of a parent/carer for the consent of children under 16.

• Are willing to maintain their normal eating/drinking habits and exercise habits to avoid changes in body weight over the duration of the study.

Exclusion Criteria:

• Manifest cardiovascular diseases including coronary artery disease, cerebrovascular disease and peripheral artery disease.

• Hypertensive, as defined as SBP superior or equal to 140 mmHg or DBP superior or equal to 90 mmHg.

• Obese participants, defined as BMI superior or equal to 30.

• Diabetes mellitus and metabolic syndrome.

• Acute inflammation, terminal renal failure or malignancies.

• Abnormal heart rhythm (lower or higher than 60-100 bpm).

• Allergies to berries or another significant food allergy.

• Subjects under medication or on vitamin/dietary supplements (within 2 weeks of baseline).

• Subjects who have lost more than 10% of their weight in the past 6 months or are currently on a diet.

• Subjects who reported participant in another study within one month before the study starts.

• Subjects who smoke cigarettes.

• MCI or dyslexic or unable to complete the cognitive function tasks for any reason such as visual impairments.

• Subjects who require chronic antimicrobial or antiviral treatment.

• Subjects with unstable psychological condition.

• Subjects with history of cancer, myocardial infarction, cerebrovascular incident.

• Any reason or condition that in the judgment of the clinical investigator(s) may put the subject at unacceptable risk or that may preclude the subject from understanding or complying with the study's requirements.

Related Conditions & MeSH terms

• Healthy

Intervention

Dietary Supplement:
• Wild Blueberry Powder
Freeze-dried whole fruit blueberry drink.
• Placebo
Freeze-dried placebo powder

Locations

Country	Name	City	State
United Kingdom	King's College London	London

Sponsors (2)

Lead Sponsor	Collaborator
King's College London	University of Reading

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Plasma blueberry (poly)phenol metabolites	Measured by liquid chromotography- mass spectrometry (LC/MS)	2 hours
Other	Urine (poly)phenol metabolites	24-hour urine samples	Baseline and 12 weeks
Primary	Cognitive function	Cognitive testing involves the participant conducting tasks administered on a tablet-style laptop. The participants will be conducting these tasks whilst cerebral blood flow measurements are taking place. The cognitive testing battery will consist of 4 tasks including a mood assessment (PANAS).	Change from baseline cognitive function at 2 hours post-consumption
Primary	Endothelial Function	Flow mediated dilation (FMD)	Change from baseline endothelial function at 2 hours post-consumption
Secondary	Cerebral blood flow (CBF)	Trans-cranial blood flow will be assessed by Non-imaging transcranial Doppler sonography (TCD)	Change of baseline cerebral blood flow at 2 hours post consumption
Secondary	Blood pressure	Automated clinical digital sphygmomanometer	Change from baseline systolic blood pressure at 2 hours post consumption